Who Owns Insulet Company?

Insulet Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Insulet Company?

Ever wondered who steers the ship at Insulet Corporation, the innovative force behind the Omnipod insulin pump? Unraveling the Insulet SWOT Analysis ownership structure is key to understanding its strategic moves and future potential. From its humble beginnings to its current status as a publicly traded entity, Insulet's ownership has undergone a fascinating transformation.

Understanding the Insulet Company ownership is crucial for investors and stakeholders alike. Knowing who owns Insulet provides insights into the company's direction and stability. This exploration will reveal the major shareholders, the evolution of Insulet Corporation owner composition, and how these elements shape Insulet's performance in the dynamic medical device market.

The Insulet Company ownership story began in 2000. John Brooks, Amparo Diaz, and Duane DeSisto founded the company with a clear mission: to simplify insulin delivery for people with diabetes. Their initial focus was on developing the Omnipod system, a tubeless insulin pump.

In 2001, Insulet secured its first major funding. The company raised $5 million in venture capital. This early investment was crucial for the development of the Omnipod system. While the exact ownership percentages of the founders at the start are not publicly available, their collective vision was key to the company's early direction.

Early backing was essential for a medical device startup like Insulet. Venture capital played a key role in funding product development. There's no public data on initial ownership disputes or significant founder buyouts during this early period. The founders' commitment to a tubeless insulin pump drove the company forward, setting the stage for its future growth and public offering. Understanding the Insulet Corporation owner structure starts with recognizing the founders' pivotal role.

Key Takeaways on Early Ownership

The founders' roles were instrumental in shaping Insulet's early direction. Venture capital was critical in the initial phase, providing the necessary financial support for product development. The focus was on creating a user-friendly diabetes management system.

• Founding Year: 2000
• Initial Funding: $5 million in 2001
• Primary Goal: Simplify insulin delivery
• Product Focus: Omnipod system

Insulet SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The Insulet Company, a prominent player in the medical device industry, officially entered the public market on May 15, 2007, through its Initial Public Offering (IPO). The IPO priced shares at $15 each, offering 8,365,000 shares of common stock. This initial offering raised $125,475,000, marking a significant milestone in the company's journey. Since its IPO, the company's market capitalization has seen substantial growth.

As of June 13, 2025, Insulet's market capitalization reached approximately $21.44 billion. This represents a remarkable increase of 5,353.65% since its IPO. The compound annual growth rate (CAGR) stands at 24.73%, highlighting the company's impressive financial performance and expansion in the market. Understanding the evolution of Insulet Company ownership is crucial for investors and stakeholders alike.

Today, the Insulet Corporation owner structure is largely dominated by institutional investors. These include mutual funds, pension funds, and hedge funds, which collectively hold a significant portion of the company's shares. As of June 13, 2025, there are 1463 institutional owners and shareholders that have filed 13D/G or 13F forms with the SEC, holding a combined total of 85,288,324 shares. The major shareholders include Vanguard Group Inc., Fmr LLC, BlackRock, Inc., and Capital Research Global Investors. Individual, or retail, investors hold a smaller percentage of shares, while company insiders, including executives and board members, own a minimal percentage. This structure suggests that major strategic and governance decisions are heavily influenced by these large investment firms. For more information on the company's target market, consider reading this article: Target Market of Insulet.

Ownership Dynamics of Insulet

Insulet's ownership structure is primarily institutional, with significant holdings by major investment firms. This influences strategic decisions and governance. The stock has shown substantial growth since its IPO.

• Institutional investors hold a majority of shares.
• Retail investors and insiders hold smaller percentages.
• The market capitalization is approximately $21.44 billion as of June 13, 2025.
• The IPO was in May 2007 at $15 per share.

Insulet PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of April 2025, the leadership of Insulet includes Ashley McEvoy as President and Chief Executive Officer, who is also a member of the Board of Directors. Timothy Scannell serves as the Independent Chairman of the Board. The board also includes members such as Elizabeth Weatherman, Flavia Pease, and Timothy Stonesifer. Flavia Pease and Timothy Stonesifer joined the board in January 2024. This structure, with both executive and independent directors, is typical for publicly traded companies.

The composition of the board reflects a focus on both operational leadership and independent oversight, which is crucial for maintaining good corporate governance. The presence of independent directors, alongside the CEO and Chairman, helps ensure a balance of perspectives in decision-making. Understanding the Competitors Landscape of Insulet is also important in the company's overall strategic direction.

Insulet, as a publicly traded company listed on NASDAQ, generally operates under a one-share-one-vote structure. This means that each share of Insulet stock carries equal voting rights. There is no public information indicating the existence of dual-class shares or special voting rights that would give disproportionate control to specific shareholders. The company holds annual stockholder meetings where shareholders vote on important matters, such as electing directors and approving executive compensation. For example, at the 2025 Annual Meeting of Stockholders on May 22, 2025, shareholders elected three Class III directors and approved the Insulet Corporation 2025 Stock Option and Incentive Plan, demonstrating ongoing shareholder support for the company's strategies.

Voting Rights and Shareholder Meetings

Insulet operates with a standard one-share-one-vote system, common for public companies. Shareholders vote on key issues at annual meetings.

• Shareholders elect directors.
• They vote on executive compensation.
• They approve strategic plans.
• The 2025 meeting saw the election of directors and approval of the 2025 Stock Option and Incentive Plan.

Insulet Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Recent developments at the Insulet Company, particularly over the past few years, offer insights into its ownership profile. A significant change in leadership occurred on April 28, 2025, with Ashley McEvoy taking over as President and CEO. This transition, along with Insulet's strong financial performance, indirectly reflects ownership trends, as major shareholders often react to significant shifts in leadership and strategic direction.

Financially, Insulet has shown robust growth. For the twelve months ending March 31, 2025, the company reported revenue of $2.199 billion, marking a 23.49% increase year-over-year. This growth is mirrored by a substantial rise in market capitalization, increasing by 77.70% as of June 13, 2025. In the first quarter of 2025, Insulet's revenue was $569 million, up 30% year-over-year. These figures suggest that the company's performance is attracting and retaining investor confidence, which is a key indicator of the stability of its ownership structure. Insulet's focus on expanding its international presence, with plans for over 10 additional country launches in 2025, also suggests a strategic focus that is likely to be supported by its major shareholders.

The company's ownership structure appears stable, with increased institutional ownership. The announcement of a $125 million share repurchase program in Q1 2025 indicates a commitment to shareholder value. Furthermore, the expansion of global manufacturing capabilities with a new facility in Malaysia underscores the company's growth strategy. Public statements and analyst reports point towards continued double-digit growth and margin expansion, which is likely to sustain investor confidence. For more information on their strategy, you can read about the Growth Strategy of Insulet.

Who Owns Insulet?

Insulet is primarily owned by institutional investors. These investors hold a significant majority of the company's shares.

Is Insulet Stock Publicly Traded?

Yes, Insulet is a publicly traded company. You can buy Insulet stock on major stock exchanges.

Insulet Leadership

Ashley McEvoy is the current President and CEO, taking over in April 2025. The company's leadership is focused on expansion.

Insulet Financials

Insulet's revenue for the twelve months ending March 31, 2025, was $2.199 billion, reflecting strong growth.

Insulet Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs